Dr. Michael B. Drummond, M.D.
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Medical school
- University of Texas Southwestern Medical School at Dallas (2001)
- Years since graduation
- 25
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 109
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2001Medical school: University of Texas Southwestern Medical School at Dallas
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
PA license MD496011 -
Critical Care Medicine (Internal Medicine) Physician
PA license MD496011
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Unc Hospitals Chapel Hill, NC
Medical groups
- University of North Carolina at Chapel Hill (2,052 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 109
- Services billed
- 320
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 72 | 60 |
| Established patient office or other outpatient visit, 40-54 minutes | 49 | 44 |
| Critical care, first 30-74 minutes | 42 | 23 |
| Test to examine how well the lungs exchange gases | 34 | 34 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 21 | 21 |
| Test to measure rate of airflow | 19 | 18 |
| New patient office or other outpatient visit, 60-74 minutes | 14 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Azithromycin Other prescribers in Pittsburgh, PA | 199 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Pittsburgh, PA | 197 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Pittsburgh, PA | 150 |
| Stiolto Respimat (tiotropium br/olodaterol hcl) Other prescribers in Pittsburgh, PA | 123 |
| Breztri Aerosphere (budesonide/glycopyr/formoterol) Other prescribers in Pittsburgh, PA | 98 |
| Prednisone Other prescribers in Pittsburgh, PA | 86 |
| Anoro Ellipta (umeclidinium brm/vilanterol tr) Other prescribers in Pittsburgh, PA | 63 |
| Spiriva Respimat (tiotropium bromide) Other prescribers in Pittsburgh, PA | 63 |
| Ventolin Hfa (albuterol sulfate) Other prescribers in Pittsburgh, PA | 58 |
| Prolastin C (alpha-1-proteinase inhibitor) | 53 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 13 payments worth $42,759 in total to this clinician.
| Takeda Pharmaceuticals U.S.A., Inc. | $13,198 |
|---|---|
| Genzyme Corporation | $10,672 |
| Verona Pharma, Inc. | $8,100 |
| Grifols Shared Services North America, Inc. | $6,888 |
| Chiesi USA, Inc. | $3,825 |
| AstraZeneca Pharmaceuticals LP | $77.06 |
| Consulting Fee | $29,228 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $12,010 |
| Travel and Lodging | $805 |
| Food and Beverage | $717 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. Mar 31, 2025 | Compensation for services other than consulting (speaking, faculty) GLASSIA · IMMUNOLOGY · in-kind | $12,010 |
| Genzyme Corporation Nov 24, 2025 | Consulting Fee | $10,127 |
| Verona Pharma, Inc. Nov 24, 2025 | Consulting Fee Ohtuvayre · Pulmonary/Respiratory Diseases | $7,200 |
| Grifols Shared Services North America, Inc. Mar 21, 2025 | Consulting Fee Prolastin-C Liquid · Pulmonology | $6,888 |
| Chiesi USA, Inc. Apr 3, 2025 | Consulting Fee | $1,913 |
| Chiesi USA, Inc. Oct 30, 2025 | Consulting Fee | $1,913 |
| Takeda Pharmaceuticals U.S.A., Inc. Feb 28, 2025 | Consulting Fee GLASSIA · IMMUNOLOGY | $1,188 |
| Verona Pharma, Inc. Nov 24, 2025 | Travel and Lodging Ohtuvayre · Pulmonary/Respiratory Diseases · travel to Chicago, IL | $763 |
| Genzyme Corporation Dec 9, 2025 | Travel and Lodging travel to Chicago, IL | $42.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $4,900 in research payments for these studies, mostly to the institutions running them.
- Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation
Genzyme Corporation · Completed · NCT03930732 - A Phase 2, Open-label Study Evaluating Efficacy and Safety of VX-864 in Subjects With Alpha-1 Antitrypsin Deficiency Who Have the PiZZ Genotype, Over 48 Weeks
Vertex Pharmaceuticals Incorporated
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.